| Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy Y Wu, M Yi, M Niu, Q Mei, K Wu Molecular cancer 21 (1), 184, 2022 | 138 | 2022 |
| Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors M Yi, M Niu, Y Wu, H Ge, D Jiao, S Zhu, J Zhang, Y Yan, P Zhou, Q Chu, ... Journal of Hematology & Oncology 15 (1), 142, 2022 | 72 | 2022 |
| Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer M Yi, Y Wu, M Niu, S Zhu, J Zhang, Y Yan, P Zhou, Z Dai, K Wu Journal for Immunotherapy of Cancer 10 (12), 2022 | 71 | 2022 |
| Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies S Zhu, M Yi, Y Wu, B Dong, K Wu Experimental Hematology & Oncology 10, 1-17, 2021 | 66 | 2021 |
| Recent advances and challenges of bispecific antibodies in solid tumors Y Wu, M Yi, S Zhu, H Wang, K Wu Experimental hematology & oncology 10 (1), 56, 2021 | 56 | 2021 |
| TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy M Yi, T Li, M Niu, Y Wu, Z Zhao, K Wu Frontiers in Immunology 13, 1061394, 2022 | 33 | 2022 |
| Recent advances in targeted strategies for triple-negative breast cancer S Zhu, Y Wu, B Song, M Yi, Y Yan, Q Mei, K Wu Journal of Hematology & Oncology 16 (1), 100, 2023 | 27 | 2023 |
| Increased expression of ECT2 predicts the poor prognosis of breast cancer patients M Yi, D Zhang, B Song, B Zhao, M Niu, Y Wu, Z Dai, K Wu Experimental Hematology & Oncology 11 (1), 107, 2022 | 9 | 2022 |
| Correction to: Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies S Zhu, M Yi, Y Wu, B Dong, K Wu Experimental Hematology & Oncology 11, 2022 | 6 | 2022 |
